Biomarkers of Alpha-Synuclein Pathology
A special issue of NeuroSci (ISSN 2673-4087).
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 3375
Special Issue Editor
Special Issue Information
Dear Colleagues,
Alpha-synuclein (a-syn) plays a key role in the pathology of Parkinson’s disease (PD), dementia with Lewy bodies (DLB), Multiple system atrophy (MSA), and other diseases. However, we are still short of biomarkers for alpha-synuclein pathology and its progression in living people. There are yet no cures for these diseases and biomarkers that can direct future therapies are urgently needed.
In PD, total a-syn levels in cerebrospinal fluid (CSF) tend to be lower compared to controls. However, inconsistent findings and a considerable interindividual variability of a-syn levels are limiting its diagnostic and prognostic value. This highlights the need for more refined a-syn biomarkers. Posttranslational modifications of a-syn and oligomeric a-syn species, alone or in combination with other markers, in CSF or other sample types, may prove to be valuable biomarker candidates. Recently, a qualitative assay for aggregation-prone a-syn with high sensitivity and specificity for synucleinopathies has emerged, opening for pre-symptomatic detection of a-syn pathology.
This special issue aims to gather studies of potential biomarkers of a-syn pathology in PD, DLB, MSA, and related diseases with emphasis on diagnostic and prognostic value, and the use of non-invasive patient samples.
Dr. Johannes Lange
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. NeuroSci is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- alpha-synuclein
- Parkinson’s disease
- dementia with Lewy bodies, Multiple system atrophy
- neurodegeneration
- biomarker
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
